Market news

Becton, Dickinson (BDX) has appointed Arthur Hu chief information and digital officer, starting Sept

Becton Dickinson (NYSE:BDX) reached an SEC cease and desist settlement over past Alaris infusion pump risk disclosures, including a civil penalty and creation of a Fair Fund for investors. Subsidiary C.R. Bard recently faced a plaintiff verdict in Bard PowerPort litigation, with thousands of related product liability cases still pending. The Alaris disclosure settlement and Bard PowerPort verdict both tie into a wider pattern of legal and compliance pressures our research tracks. We have...

Becton Dickinson & Co (NYSE:BDX) recently announced a total dividend of $1.05 per share, with the ex-dividend date set for 2026-09-09. This cash dividend is payable on 2026-09-30. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

Becton Dickinson (NYSE:BDX) has become a founding sponsor of a new Medicinal Hazard Data Standardization Consortium focused on hazardous drug information. The global initiative aims to create standardized Medicinal Hazard Data Sheets to reduce data fragmentation and support safer handling of hazardous medicines for healthcare workers. Several major healthcare companies are joining BD in the consortium, which is expected to influence future regulatory and clinical best practice...

Becton Dickinson (BDX) is in focus after announcing completion of patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first in class option for preventing incisional hernias. See our latest analysis for Becton Dickinson. The PREVENT milestone comes after a series of recent updates around Becton Dickinson, including new quality leadership appointments, conference appearances and a recall-related correction notice. It also comes against a backdrop of a 30 day share...

Becton Dickinson stock has delivered a 25.4% return over the past year, while current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. Over the last 12 months, Becton Dickinson has returned 25.4%, which puts recent gains in focus when assessing how much upside may remain. Progress on the PREVENT clinical trial can support long term cash flow expectations, while the recent recall of...

Becton Dickinson (NYSE:BDX) reported completion of patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for prevention of incisional hernias. The large scale study is designed to assess the safety and effectiveness of Phasix Mesh as a prophylactic option in patients undergoing abdominal surgery. Finishing enrollment moves the trial closer to data readout and potential regulatory review for what the company positions as a first of its kind product in this category. The...

Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Becton Dickinson’s buy rating is reaffirmed as its clinical portfolio grows, Fitch improves risk, and stock momentum returns. Click to read this latest update.

Becton, Dickinson (BDX) will take 12 to 18 months to have consistent mid-single-digit organic growth

Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.

On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC’s Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That’s the big medical technology and supply play… That was formerly known as Becton, Dickson. This was the first full quarter […]

BDX beats expectations with 4.4% FX-neutral revenue growth, raises full-year EPS guidance, and outlines strategic plans to navigate fiscal 2027 headwinds.

Becton, Dickinson and Company (NYSE:BDX) reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company’s expectations. Chairman, Chief Executive Officer and President Tom Po

Moby summary of Becton, Dickinson and Company's Q3 2026 earnings call

Becton Dickinson raises 2026 adjusted EPS guidance after reporting Q3 revenue growth across core medical and interventional business segments.

The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Becton Dickinson (BDX) delivered earnings and revenue surprises of +2.87% and +1.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Becton, Dickinson (BDX) reported fiscal Q3 adjusted earnings from continuing operations Thursday of

Becton Dickinson: Fiscal Q3 Earnings Snapshot

Evaluate the expected performance of Becton Dickinson (BDX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.